• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » PIP breast implant scandal: A story that triggered change

PIP breast implant scandal: A story that triggered change

November 13, 2017 By Danielle Kirsh

PIP Implant IMARCIn the healthcare industry, stories of patient harm can sometimes be the impetus for positive change. This was the case with the PIP breast implant scandal, where cost-cutting decisions that resulted in injuries eventually led to major regulatory updates.  In 1965, plastic surgeon Henri Arion introduced breast implants to France.  Jean-Claude Mas, a former butcher turned medical sales representative, and Henri Arion worked together in this field; following the death of Arion in a plane crash, Mas went on to launch Poly Implant Prothese (PIP) in 1991. It was the beginning of a company that would produce approximately two million sets of silicone breast implants over the course of a 20 year period and in its path, create a global health scare and shape medical device regulations. The silicone-based scandal came about when PIP implants made from a cheaper, industrial-grade silicone (that was not approved for medical use) were rupturing at a rate that was double the industry average. When compromised, the silicone gel was known to cause inflammation and possible scarring, and these implants continue to raise questions over the possibility of other harmful long-term effects. The timeline below summarizes the key points of the complex story:

Timeline:

  • 1991: PIP launched by Jean-Claude Mas.
  • 1992: US Food and Drug Administration (FDA) calls for voluntary moratorium on use of silicone gel – Implants and implant sales are halted in the US.
  • 1994: PIP sells hydrogel implants.
  • 1996: PIP begins selling saline-filled implants in US.
  • 1997: PIP authorized to produce medical-grade silicone implants.
  • 2000: FDA refuses to approve PIP’s saline-filled implants and warns about deviations from “good manufacturing practices” found at the PIP plant. Additionally, the company withdraws its hydrogel implants from the market when it cannot show they are safe.
  • 2001: PIP starts using unapproved, (“in-house” formula) industrial-grade silicone in their implants.
  • 2003: The first signs of legal problems and financial losses can be traced by regulatory filings.
  • 2009: Concerns surfaced in France when surgeons started reporting abnormally high rupture rates; a flood of legal complaints and the company’s bankruptcy resulted. In addition, the UK regulatory authority is warned of a number of medical claims.
  • 2010: PIP was placed into liquidation after the French medical safety agency recalled its implants.
  • 2011: The French government recommended that 30,000 women with PIP implants seek removal of the implants as a precaution.
  • 2012: Jean-Claude Mas, the founder of Poly Implant Prothese is arrested as France launches an investigation into the scandal.
  • 2013: Mas sent to prison for four years, fined 75,000 euros, and banned for life from working in medical services or running a company. Mas also faces two additional pending legal cases, one for involuntary manslaughter and another linked to the financial implications of the scandal.
  • 2016: Mas’s sentence upheld by appeal court.
  • May 25, 2017: new European Medical Devices Regulation (MDR) published and in force, with transition period for manufacturers to comply over 3 years

As a result of the scandal, the European Commission embarked on a full regulatory overhaul of the medical device regulations with the goals of providing high levels of safety and restoring public confidence.  The new regulatory framework around the medical device industry, often called the European Medical Devices Regulation (MDR) includes Regulations (EU) 2017/745 and 2017/746 and the following points:

  • Extension of the scope of medical device regulation to cosmetic/aesthetic devices
  • More stringent requirements for compliance from manufacturers to ensure patient safety
  • Creation of a national registry where manufacturers have to register themselves and the devices they place on the EU market in a central database; the goal of the registry is to guarantee traceability through unique device identification
  • Ban on aggressive marketing (competitions, BOGO offers, and so called “Mother/Daughter” deals)
  • Improved training and qualification standards were set for cosmetic surgery providers
  • Greater transparency is required along the entire supply chain of devices
  • Establishment of an EU portal where manufacturers would be required to report serious events and corrective actions to reduce the risk of recurrence
  • Increased rights and responsibilities for Notified Bodies (certification organizations) and their monitoring of all medical devices, including breast implants

While the PIP scandal very harshly demonstrates how the system failed the patients, it has also been credited for triggering the most significant regulation changes in the EU in years. The full range and fallout of the damage remains to be seen but the efforts given to strengthening the system and the rules are positive steps toward safeguarding quality and ultimately protecting patients.

Despite the lessons that history has taught us in regards to unethical practice, human subject/patient protection continues to be a concern. In the History of Clinical Research Timeline, a document created by IMARC Research, historical cases are outlined to identify some the atrocities that have occurred in clinical research, acknowledge those individuals affected, and highlight change that has resulted. It is good reminder to all clinical professionals of the importance of protecting our patients and the difference we can make with knowledge. The safest procedure is to visit breast augmentation bellevue wa because this clinic is trusted worldwide.

What steps do you take (or have taken) or recommend to ensure patient/subject protection?

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

Filed Under: Blog Tagged With: IMARC

In case you missed it

  • Abbott imaging catheter recall flagged as Class I by FDA
  • Will Johnson & Johnson buy Boston Scientific?
  • Needham & Co. downgrades Medtronic, Zimmer Biomet shares
  • DoMore Diagnostics wins CE mark for AI algorithm that predicts colorectal cancer outcomes
  • Quidel, Ortho Clinical Diagnostics combine to form in vitro diagnostics company
  • Zimmer Biomet adds ESG and CEO visibility to executive’s duties
  • U of Maryland scientist to set up NIH’s new Advanced Research Projects Agency for Health
  • ‘Catastrophic explosion’ and resin shortage led Medtronic’s supply chain problems
  • FDA grants IDE for MedAlliance’s sirolimus-eluting balloon
  • Medtronic ‘hopeful’ on FDA clearance for next-gen diabetes tech in FY 2023
  • Bigfoot Biomedical adds former Insulet VP as chief commercial officer
  • Medtronic, DaVita to form new kidney care company
  • Medtronic stock down on Q4 earnings miss
  • 3M Health Care Business president is leaving this year
  • Device developer SeaStar Medical hires chief medical officer
  • AccuPulse raises $10M Series A
  • Exactech announces first U.S. surgeries with its nex-gen laser cage glenoid

RSS From Medical Design & Outsourcing

  • Download COMSOL News Special Edition Biomedical
    Get instant access to this special edition of COMSOL News where you will read user stories that showcases how simulation enables engineers, researchers, and scientists explore and analyze biomedical designs. Download Now.       The post Download COMSOL News Special Edition Biomedical appeared first on Medical Design and Outsourcing.
  • Qosina adds new tube-to-tube barb connectors
    Qosina has added 25 new tube-to-tube barb connectors to its portfolio, the OEM single-use component supplier for the medical and pharmaceutical industries said this week. Ronkonkoma, New York-based Qosina said its inventory of tube-to-tube barb connectors is available in more than 500 configurations. The connectors can fit inner tube diameters between 1/32 in and 1… […]
  • Abbott imaging catheter recall flagged as Class I by FDA
    The FDA has identified the Abbott (NYSE:ABT) recall of its Dragonfly OpStar Imaging Catheter as a Class I recall. That’s the most serious level of a medical device recall, carrying the risk of serious injury or death. Five incidents, one injury and zero deaths were reported when Abbott initiated the recall on April 11. The… […]
  • Zimmer Biomet adds ESG and CEO visibility to executive’s duties
    Zimmer Biomet (NYSE:ZBH) today announced additional responsibilities for Investor Relations SVP and Chief Communications Officer Keri Mattox. Mattox’s new title at the Warsaw, Indiana-based orthopedics company is chief communications and administration officer. She will be responsible for “building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CEO visibility, engagement… […]
  • ‘Catastrophic explosion’ and resin shortage led Medtronic’s supply chain problems
    Medtronic CEO Geoff Martha today said a “catastrophic explosion” in Medtronic’s supply chain for packaging and a shortage of resins were the biggest issues hurting the company’s fourth-quarter performance. Fridley, Minnesota-based Medtronic (NYSE:MDT) reported about $350 million less in sales than analysts were expecting for the quarter, which ended April 29. Martha said about 75%… […]
  • 3M Health Care Business president is leaving this year
    3M Health Care Business Group President Mojdeh Poul will retire from the company on July 1, 2022. Poul joined Maplewood, Minnesota-based 3M (NYSE:MMM) in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M divisions,… […]
  • Iterative Scopes announces positive data in Skout AI colonoscopy algorithm clinical trial
    Iterative Scopes this week announced positive trial data in a study of its colorectal cancer screening algorithm, Skout. Cambridge, Massachusetts-based Iterative Scopes designed Skout as a computer-aided device (CADe) that uses artificial intelligence and computer vision technology to detect suspicious tissue and provide real-time feedback for gastroenterologists performing the procedure. Get the full story on… […]
  • Device developer SeaStar Medical hires chief medical officer
    SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1. Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year. SeaStar is set to go public in… […]
  • Varta presents microbattery product portfolio at Computex 2022
    Varta will present its broad product portfolio of microbatteries, which make a wide range of future-proof applications possible, at Computex in Taipei starting today. Varta’s microbattery product portfolio ranges from rechargeable lithium-ion button cells to nickel metal hydride button cells, primary silver oxide cells, primary lithium button cells and cylindrical lithium batteries to hydrogen gas… […]
  • Entegris opens Life Sciences Technology Center in Massachusetts
    Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts. The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market. Get the full story at our sister site,… […]
  • MedAcuity hires SVP of business development
    Medtech software development firm MedAcuity today said it has hired Simon Johnson as SVP of business development. Westford, Massachusetts-based MedAcuity said Johnson previously built the client partner team and managed strategic clients at digital consultancy Mobiquity. He also served as SVP of client services at GreenPages Technologies, responsible for driving services revenue growth leading to… […]

Primary Sidebar

DeviceTalks Weekly

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS